NEW YORK, March 29 (GenomeWeb News) - Metabolon and Massachusetts General Hospital hope to co-discover biomarkers for diabetic nephropathy in type I diabetes, Metabolon said today.
The study has been funded by a two-year grant awarded to MGH's Darryl Palmer-Toy by the National Institute of Diabetes and Digestive and Kidney Diseases. The amount of funding for fiscal year 2004, which began on Oct. 1, is worth $365,000.
Metabolon will test patient urine and plasma samples with its metabolomics platform to search for signatures that predict the likelihood of developing diabetic nephropathy, Metabolon said.
This is the second collaboration announced between Metabolon and MGH in the past year. In August, Metabolon and MGH announced a collaborative biomarker study for amyotrophic lateral sclerosis.